HALO vs. JAZZ: Halozyme Therapeutics vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Jazz Pharmaceuticals (JAZZ) at 5.05%, which is closer to a typical peer reading.

Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

Both Halozyme Therapeutics (HALO) at 59.84% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Halozyme Therapeutics (HALO) at -25.36% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.

Only one side’s leverage can be read here: Jazz Pharmaceuticals (JAZZ) carries debt-to-equity ratio of 1.35 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Halozyme Therapeutics (HALO) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Halozyme Therapeutics (HALO) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 3.59, ranking against industry peers normally.

Valuation Metrics